Dr. Joseph L. Newberg, MD
Emergency Medicine (Emergency Medicine Physician)
1007 Lincolnway
La Porte, IN 46350
Who else practices at this address →
LaPorte County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 126
Licensed in Illinois since 2000, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
IN license 01070517A · IL license 036103527 (first issued 2000; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
- Community Hospital Munster, IN
Medical groups
- University of Chicago (1,712 clinicians)
- Community Care Network Inc (379 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 126
- Services billed
- 209
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 205 | 200 |
| Established patient office or other outpatient visit, 30-39 minutes | 113 | 113 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus and influenza | 68 | 67 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 28 | 28 |
| Routine electrocardiogram (ecg) using at least 12 leads with tracing | 20 | 20 |
| Automated urinalysis test | 19 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 18 | 18 |
| Injection of drug or substance under skin or into muscle | 12 | 12 |
| New patient office or other outpatient visit, 30-44 minutes | 12 | 12 |
| Detection test by immunoassay with direct visual observation for respiratory syncytial virus | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methylprednisolone Other prescribers in La Porte, IN | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 8 payments worth $1,501 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,501 |
|---|
| Travel and Lodging | $1,241 |
|---|---|
| Food and Beverage | $260 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 9, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Phoenix, AZ · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $527 |
| Merck Sharp & Dohme LLC Sep 9, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Phoenix, AZ · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $334 |
| Merck Sharp & Dohme LLC Sep 9, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Phoenix, AZ · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $241 |
| Merck Sharp & Dohme LLC Sep 10, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Phoenix, AZ · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $140 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 8 companies. The companies reported $1,137,262 in research payments for these studies, mostly to the institutions running them.
- Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older
Sanofi Pasteur Inc. · Completed · NCT06695117 - A phase 3 multicenter parallelgroup openlabel study to evaluate the safety tolerability and immunogenicity of respiratory syncytial virus prefusion f subunit vaccine when coadministered with herpes zoster subunit vacc…
Pfizer Inc. - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc. - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
Vertex Pharmaceuticals Incorporated - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
Sanofi Pasteur Inc. · Terminated · NCT04904549 - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD
Novartis Pharmaceuticals Corporation - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.